XML 34 R8.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Condensed Consolidated Financial Statements Detail | 9 Months Ended
--- | ---
Sep. 30, 2015
Condensed Consolidated Financial Statements Detail [Abstract] |
Condensed Consolidated Financial Statements Detail | 3. Condensed Consolidated Financial Statements Detail Net Loss Per Share of Common Stock Basic net loss per share of common stock is based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is based on the weighted average number of shares of common stock outstanding during the period, adjusted to include the assumed conversion of certain stock options, restricted stock units (“RSUs”), and warrants for common stock. The calculation of diluted loss per share of common stock also requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of such securities are dilutive to earnings (loss) per share for the period, adjustments to net income or net loss used in the calculation are required to remove the change in fair value of the warrants for the period. Likewise, adjustments to the denominator are required to reflect the related dilutive shares. Potentially dilutive securities are excluded from the calculation of diluted net loss per share of common stock if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share of common stock (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2015 |  |  | 2014 |  |  | 2015 |  |  | 2014 |
Common stock options and RSUs |  |  | 10,972 |  |  |  | 8,037 |  |  |  | 9,623 |  |  |  | 6,601 |
Warrants for common stock |  |  | 18,166 |  |  |  | 1,910 |  |  |  | 18,166 |  |  |  | 1,910 |
Total |  |  | 29,138 |  |  |  | 9,947 |  |  |  | 27,789 |  |  |  | 8,511 |
The following is a reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2015 |  |  | 2014 |  |  | 2015 |  |  | 2014 |
Numerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | (480 | ) |  | $ | (14,399 | ) |  | $ | (45,958 | ) |  | $ | (30,983 | )
Adjustment for revaluation of contingent warrant liabilities |  |  | — |  |  |  | (5,360 | ) |  |  | — |  |  |  | (32,510 | )
Diluted |  | $ | (480 | ) |  | $ | (19,759 | ) |  | $ | (45,958 | ) |  | $ | (63,493 | )
Denominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares outstanding used for basic net loss per share |  |  | 118,552 |  |  |  | 107,208 |  |  |  | 117,437 |  |  |  | 106,768 |
Effect of dilutive warrants |  |  | — |  |  |  | 7,115 |  |  |  | — |  |  |  | 8,108 |
Weighted average shares outstanding and dilutive securities used for diluted net loss per share |  |  | 118,552 |  |  |  | 114,323 |  |  |  | 117,437 |  |  |  | 114,876 |
Cash and Cash Equivalents As of September 30, 2015, cash and cash equivalents consisted of demand deposits of $20.0 million and money market funds of $12.1 million with maturities of less than 90 days at the date of purchase. As of December 31, 2014, cash and cash equivalents consisted of demand deposits of $10.8 million and money market funds of $67.6 million with maturities of less than 90 days at the date of purchase. Accrued and Other Liabilities Accrued and other liabilities consisted of the following (in thousands):
|  | September 30, 2015 |  |  | December 31, 2014 |
Accrued payroll and other benefits |  | $ | 2,965 |  |  | $ | 3,061 |
Accrued management incentive compensation |  |  | 2,663 |  |  |  | 4,295 |
Accrued restructuring costs |  |  | 1,742 |  |  |  | — |
Accrued clinical trial costs |  |  | 576 |  |  |  | 1,424 |
Other |  |  | 1,734 |  |  |  | 1,112 |
Total |  | $ | 9,680 |  |  | $ | 9,892 |
Contingent Warrant Liabilities In December 2014, in connection with a registered direct offering to select institutional investors, the Company issued two-year warrants to purchase up to an aggregate of 8,097,165 shares of XOMA’s common stock at an exercise price of $7.90 per share. These warrants contain provisions that are contingent on the occurrence of a change in control, which could conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company accounts for the warrants issued in December 2014 as a liability at fair value. In addition, the estimated fair value of the liability related to the warrants is revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders’ equity, or expiration of the warrants. As of December 31, 2014, 8,097,165 of these warrants were outstanding and had a fair value of $5.2 million. The Company revalued the warrants at September 30, 2015 using the Black-Scholes Model and recorded a $4.2 million decrease in the fair value as a gain in the revaluation of contingent warrant liabilities line of the Company’s condensed consolidated statements of comprehensive loss. The decrease in liability is primarily due to the decrease in the market price of XOMA’s common stock at September 30, 2015 as compared to December 31, 2014. At September 30, 2015, 8,097,165 of these warrants were outstanding and had a fair value of $1.0 million. In March 2012, in connection with an underwritten offering, the Company issued five-year warrants to purchase 14,834,577 shares of XOMA’s common stock at an exercise price of $1.76 per share. These warrants contain provisions that are contingent on the occurrence of a change in control, which could conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company accounts for the warrants issued in March 2012 as a liability at fair value. In addition, the estimated liability related to the warrants is revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At December 31, 2014, warrants to purchase 12,109,418 shares were outstanding and had a fair value of $26.7 million. During the nine months ended September 30, 2015, warrants to purchase 2,524,265 of common stock were exercised, of which 2,523,515 were cashless exercises, resulting in an issuance of 1,410,474 shares of common stock. The Company revalued the warrants immediately prior to the exercise dates and recognized $2.2 million as a gain from the revaluation of contingent warrant liabilities. The remaining balance of $3.6 million was reclassified from contingent warrant liabilities to stockholders’ (deficit) equity on the condensed consolidated balance sheet due to the exercise of the warrants. The Company revalued the remaining warrants at September 30, 2015 using the Black-Scholes Model and recorded a $20.0 million decrease in the fair value as a gain in the revaluation of contingent warrant liabilities line of the Company’s condensed consolidated statements of comprehensive loss. This decrease in liability is primarily due to the decrease in the market price of XOMA’s common stock at September 30, 2015 compared to December 31, 2014. At September 30, 2015, 9,585,153 of the warrants were outstanding and had a fair value of $3.1 million. In February 2010, in connection with an underwritten offering, the Company issued five-year warrants to purchase 1,260,000 shares of XOMA’s common stock at an exercise price of $10.50 per share. The warrants contain provisions that are contingent on the occurrence of a change in control, which could conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company accounted for the warrants as liabilities at fair value. At December 31, 2014, all of these warrants were outstanding and their fair value was de minimis. All of these warrants expired unexercised in February 2015.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | xoma_CondensedConsolidatedFinancialStatementsDetailAbstract
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration